title: Three new active cisplatin-containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial.
abstract: We designed three new four-drug cisplatin-containing combinations and evaluated their activity in a randomized phase II study including patients with locally advanced (stage III) and locally recurrent breast carcinoma. All combinations included methotrexate (M) on day 1 and cisplatin (P) on day 2 (MVAC-like combinations) and differed from one another by the addition of Epirubicin (Epi), Vincristine (V), Etoposide (E), Mitomycin (Mi). Based on the administered agents, they were named MPEMi, MPEpiE, MPEpiV. The combinations were randomly assigned to 101 patients, 57 with locally advanced and 44 with locally recurrent breast carcinoma. Response was evaluated after 4 cycles. The complete response (CR) rates were 7% and 43% and the CR plus partial response (PR) rates were 84% and 89% in locally advanced and in locally recurrent disease, respectively. In locally advanced disease, a pathologic CR (pCR) was assessed in seven of 57 patients (12%). There were no significant differences among the three combinations. The toxicities were at times severe, but generally tolerable, as demonstrated by the high cumulative doses of the drugs received by the patients. In conclusion, these three innovative chemotherapy regimens induced high CR plus PR rates in the neoadjuvant treatment of stage III and of locally recurrent breast carcinoma, and a high rate of pCR in stage III disease. These regimens warrant testing in phase III trials.
authors.affiliation: Medical Oncology Institution of Parma, Italian Oncology Group for Clinical Research (GOIRC), Italy. oncolog@ipruniv.cce.unipr.it
authors.forename: G
authors.initials: G
authors.lastname: Cocconi
authors.forename: G
authors.initials: G
authors.lastname: Bisagni
authors.forename: G
authors.initials: G
authors.lastname: Ceci
authors.forename: B
authors.initials: B
authors.lastname: Di Blasio
authors.forename: V
authors.initials: V
authors.lastname: De Lisi
authors.forename: R
authors.initials: R
authors.lastname: Passalacqua
authors.forename: A
authors.initials: A
authors.lastname: Zadro
authors.forename: C
authors.initials: C
authors.lastname: Boni
authors.forename: P
authors.initials: P
authors.lastname: Morandi
authors.forename: L
authors.initials: L
authors.lastname: Savoldi
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D002945:Cisplatin / Q000008:administration & dosage; D015251:Epirubicin / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D014750:Vincristine / Q000008:administration & dosage
chemical_list: D015251:Epirubicin; D016685:Mitomycin; D014750:Vincristine; D005047:Etoposide; D002945:Cisplatin; D002955:Leucovorin; D008727:Methotrexate